| Primary |
| Local Anaesthesia |
32.4% |
| Anaesthesia |
13.3% |
| Immunisation |
11.4% |
| Analgesic Therapy |
3.8% |
| Circumcision |
3.8% |
| Laser Therapy |
3.8% |
| Molluscum Contagiosum |
3.8% |
| Sedative Therapy |
3.8% |
| Systemic Lupus Erythematosus |
3.8% |
| Depilation |
2.9% |
| Pain |
2.9% |
| Application Site Anaesthesia |
1.9% |
| Nuclear Magnetic Resonance Imaging |
1.9% |
| Petit Mal Epilepsy |
1.9% |
| Prostatitis |
1.9% |
| Stupor |
1.9% |
| Wound Complication |
1.9% |
| Anaemia |
1.0% |
| Blood Electrolytes |
1.0% |
| Blood Immunoglobulin G Decreased |
1.0% |
|
| Methaemoglobinaemia |
14.5% |
| Overdose |
14.5% |
| Penile Erythema |
10.9% |
| Syncope |
9.1% |
| Malaise |
7.3% |
| Cerebrovascular Accident |
3.6% |
| Convulsion |
3.6% |
| Erythema |
3.6% |
| Generalised Erythema |
3.6% |
| Nausea |
3.6% |
| Paraesthesia |
3.6% |
| Skin Burning Sensation |
3.6% |
| Skin Warm |
3.6% |
| Somnolence |
3.6% |
| Angioedema |
1.8% |
| Application Site Erythema |
1.8% |
| Application Site Rash |
1.8% |
| Application Site Reaction |
1.8% |
| Application Site Vesicles |
1.8% |
| Arrhythmia |
1.8% |
|
| Secondary |
| Product Used For Unknown Indication |
46.1% |
| Drug Exposure Via Mother |
21.9% |
| Local Anaesthesia |
8.6% |
| Anaesthesia |
5.5% |
| Skin Wrinkling |
3.1% |
| Drug Use For Unknown Indication |
1.6% |
| Fear Of Needles |
1.6% |
| Induction Of Anaesthesia |
1.6% |
| Malaria Prophylaxis |
1.6% |
| Parenteral Nutrition |
1.6% |
| Premedication |
1.6% |
| Wound Complication |
1.6% |
| Acute Leukaemia |
0.8% |
| Foetal Growth Restriction |
0.8% |
| Hyperthermia |
0.8% |
| Nausea |
0.8% |
| Neuralgia |
0.8% |
|
| Drug Exposure During Pregnancy |
7.7% |
| Injection Site Pain |
7.7% |
| Injection Site Swelling |
7.7% |
| Maternal Drugs Affecting Foetus |
7.7% |
| Premature Baby |
7.7% |
| Vomiting |
7.7% |
| Wheezing |
7.7% |
| Drug Hypersensitivity |
3.8% |
| Foetal Growth Restriction |
3.8% |
| Hypersensitivity |
3.8% |
| Infantile Apnoeic Attack |
3.8% |
| Maternal Exposure Timing Unspecified |
3.8% |
| Pancreatitis Acute |
3.8% |
| Panniculitis |
3.8% |
| Psychotic Disorder |
3.8% |
| Staphylococcal Infection |
3.8% |
| Staphylococcus Test Positive |
3.8% |
| Tachycardia Foetal |
3.8% |
| Urinary Retention |
3.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.5% |
| Drug Use For Unknown Indication |
14.2% |
| Pain |
8.8% |
| Nausea |
8.2% |
| Prophylaxis |
6.0% |
| Breast Cancer |
4.2% |
| Premedication |
3.4% |
| Acute Lymphocytic Leukaemia |
3.3% |
| Sedation |
2.9% |
| Non-small Cell Lung Cancer |
2.7% |
| Hypertension |
2.6% |
| Arthritis |
2.0% |
| Foetal Exposure During Pregnancy |
2.0% |
| Maternal Exposure Timing Unspecified |
2.0% |
| Muscle Spasms |
2.0% |
| Rash |
1.7% |
| Constipation |
1.6% |
| Eczema |
1.6% |
| Hypercalcaemia |
1.6% |
| Glioblastoma Multiforme |
1.6% |
|
| Vomiting |
13.8% |
| Pulmonary Embolism |
8.8% |
| Urinary Tract Infection |
8.3% |
| Pyrexia |
7.7% |
| Weight Increased |
7.2% |
| Rash |
6.1% |
| Vision Blurred |
5.5% |
| Swelling |
4.4% |
| Breast Cancer |
3.9% |
| White Blood Cell Count Decreased |
3.9% |
| Death |
3.3% |
| Hypotension |
3.3% |
| Injection Site Swelling |
3.3% |
| Pancytopenia |
3.3% |
| Tachycardia |
3.3% |
| Anaemia |
2.8% |
| Ascites |
2.8% |
| Hypertension |
2.8% |
| Sepsis |
2.8% |
| Thrombocytopenia |
2.8% |
|
| Interacting |
| Affective Disorder |
25.0% |
| Factor Ix Deficiency |
25.0% |
| Injection Site Anaesthesia |
25.0% |
| Splenectomy |
25.0% |
|
| Wrong Technique In Drug Usage Process |
100.0% |
|
